Manufacturing of Eliquis involves complex chemical synthesis processes to produce the active pharmaceutical ingredient, apixaban, and its formulation into a finished dosage form. This process is carried out by the drug's developers and manufacturers, Bristol Myers Squibb and Pfizer [1].
How is Eliquis (Apixaban) Made?
The synthesis of apixaban, the active ingredient in Eliquis, requires a multi-step chemical process. While specific proprietary details are not publicly disclosed, the general approach involves the assembly of molecular components through various chemical reactions. These reactions are conducted under controlled conditions to ensure the purity and potency of the apixaban. Once the active pharmaceutical ingredient is synthesized, it is then formulated into tablets, which involves blending apixaban with inactive ingredients (excipients) and compressing this mixture into the final dosage form [2].
Who Manufactures Eliquis?
Eliquis is co-developed and co-marketed by Bristol Myers Squibb and Pfizer [1]. Both companies have established manufacturing facilities and processes to produce Eliquis for global markets.
When Does Eliquis Patent Protection End?
Patent protection for Eliquis has a complex landscape with various patents covering different aspects of the drug, including its composition, method of use, and manufacturing processes. According to DrugPatentWatch.com, the key patents for Eliquis are set to expire at different times, with significant patent expiries anticipated in the coming years [3]. For example, some composition of matter patents may expire around 2026, while other method of use or formulation patents could extend longer. These patent expiries are crucial for the potential market entry of generic versions of apixaban [3].
What are the Risks of Eliquis Manufacturing?
The manufacturing of any pharmaceutical product, including Eliquis, carries inherent risks. These can include challenges in maintaining consistent product quality and purity throughout the synthesis and formulation stages, ensuring compliance with stringent regulatory requirements, and managing supply chain disruptions. Additionally, the complex chemical processes involved may pose environmental and safety risks that require careful management and mitigation strategies [2].
Can Generic Eliquis Be Manufactured Before Patent Expiry?
Generally, generic versions of a drug cannot be manufactured and marketed until the relevant patent protections have expired, or until patent litigation resolves in favor of the generic manufacturer. The exact timing for the availability of generic Eliquis depends on the expiration dates of its core patents and any potential legal challenges that may arise. DrugPatentWatch.com tracks these patent statuses, which are essential for understanding when generic competition might emerge [3].